Biosimilar Glargine Insulin: Implications for Prescribers and Patients

被引：1
|
作者：
Pereira, Katherine [1 ,2 ]
机构：
[1] Duke Univ, Sch Nursing Durham, Durham, NC 27708 USA
[2] Duke Univ, Sch Nursing Durham, Doctor Nursing Practice Program, Div Endocrinol Metab & Nutr, Durham, NC 27708 USA
来源：
JNP-JOURNAL FOR NURSE PRACTITIONERS | 2017年 / 13卷 / 03期
关键词：
FOLLOW-ON-BIOLOGICS; COMPETITION;
D O I：
10.1016/j.nurpra.2016.11.022
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：236 / 237
页数：2
相关论文
共 50 条
  • [41] Therapy with insulin glargine in cystic fibrosis (CF) patients
    Minicucci, L
    De Alessandri, A
    Casciaro, R
    Burlando, O
    Lugani, F
    Lorini, R
    DIABETES, 2005, 54 : A520 - A520
  • [42] Comparison of Prandial AIR Inhaled Insulin Alone to Intensified Insulin Glargine Alone and to AIR Insulin Plus Intensified Insulin Glargine in Patients with Type 2 Diabetes Previously Treated with Once-Daily Insulin Glargine
    Rosenstock, Julio
    Eliaschewitz, Freddy G.
    Heilmann, Cory R.
    Muchmore, Douglas B.
    Hayes, Risa P.
    Belin, Ruth M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2009, 11 : S63 - S73
  • [43] Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union
    Byrd, Richard A.
    Owens, Rebecca A.
    Blackbourne, Jamie L.
    Coutant, David E.
    Farmen, Mark W.
    Michael, M. Dodson
    Moyers, Julie S.
    Schultze, A. Eric
    Sievert, Michael K.
    Tripathi, Niraj K.
    Vahle, John L.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2017, 88 : 56 - 65
  • [44] Glargine Utilization in Russia: A Retrospective Comparative Study To Evaluate Patients Switched from NPH Insulin to Insulin Glargine Compared with Patients Maintained on NPH
    Jarek-Martynowa, Iwona
    Shamkhalova, Minara
    Shestakova, Marina
    DIABETES, 2011, 60 : A608 - A608
  • [45] Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
    Wang, Yiya
    Zhou, Ying
    Ding, Juefang
    Li, Xianjing
    Guo, Fengxue
    Zhang, Jianfei
    Ding, Li
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [46] Traceability of insulin glargine's innovator and its biosimilar products adverse drug events reports in Saudi Arabia
    Alrubaish, Fares
    Alhawas, Solaiman
    Alnuaim, Abdulrahman
    Alfadel, Nouf
    Alharbi, Fawaz F.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 488 - 488
  • [47] On the safety of insulin Glargine
    Dedov, I. I.
    Shestakova, M. V.
    Peterkova, V. A.
    DIABETES MELLITUS, 2009, 12 (03): : 94 - 94
  • [48] Insulin glargine (Lantus®)
    Owens, DR
    Griffiths, S
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (06) : 460 - 466
  • [49] Insulin glargine and cancer
    Hemkens, Lars G.
    Bender, Ralf
    Grouven, Ulrich
    Sawic, Peter T.
    LANCET, 2009, 374 (9703): : 1743 - 1744
  • [50] Poisoning with insulin glargine
    Brvar, M
    Mozina, M
    Bunc, M
    CLINICAL TOXICOLOGY, 2005, 43 (03): : 219 - 220
12345